Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-satoreotide trizoxetan
- Development stage
- Phase 1
- Lead developer
- Ariceum Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-satoreotide trizoxetan is a **radiopharmaceutical imaging agent** composed of the somatostatin receptor antagonist peptide satoreotide trizoxetan (OPS202) labeled with the positron-emitting radionuclide gallium-68. Its **mechanism of action** is selective binding to **somatostatin receptor subtype 2 (SSTR2)**, which is overexpressed in neuroendocrine tumors (NETs) and certain aggressive cancers. This allows targeted **PET imaging** of SSTR2-positive tumors, resulting in higher tumor-to-background ratios and sensitivity for lesion detection compared to somatostatin receptor agonists. Developed and currently manufactured by Ariceum Therapeutics, this agent is used for diagnostic imaging in NETs and is being explored as a component in theranostic pairs for combined diagnosis and therapy in neuroendocrine malignancies, including small cell lung cancer and high-grade neuroendocrine lung cancer[1][2][3][5][7].
- Brand names
- 68Ga-satoreotide trizoxetanGallium Ga 68 Satoreotide Trizoxetan
- Other names
- SATOREOTIDE TRIZOXETAN GALLIUM GA-68Gallium Ga 68 OPS202Gallium Ga 68 NODAGA-JR11
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 68Ga-satoreotide trizoxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-satoreotide trizoxetan.